Hey there, it’s Vadim 👋

This week on the Bio Founder GPS podcast, I got to sit down with Elena Itskovich, PhD, Founding General Partner of Nest Catalyst.

For anyone that hasn’t checked it out yet, Nest Catalyst is an entrepreneurship program built specifically for scientist-founders making the leap from the lab into company creation.

Across several cohorts, Elena has worked with early-career scientists as they begin navigating all the pieces that rarely get taught in grad school or a postdoc: selecting a market, shaping a company story, finding mentors, thinking through IP, understanding fundraising, and building the confidence to build and lead.

What I appreciated about Elena’s perspective is that she sees founders at a very formative stage.

The company may exist, but the story is still taking shape. The science may be strong, but the first market or indication may still be uncertain. The founder may already be doing the work, but may not fully feel like “the CEO” yet.

That stage is messy, but it’s also where a lot of the important decisions happen.

What problem are you really solving? Where should the company start? How much of the academic path should carry forward, and what needs to change? When should you start talking to investors? And how do you know when you’re actually ready to raise?

This is exactly what we dug into, and I so appreciated Elena’s unique insights on what founders can do to move their sciences, and their companies, forward.

🧭 HERE’S WHAT WE COVERED:

  • Why scientist-founders may be more prepared for company-building than they realize

  • The shift from academic validation to founder ownership

  • How to think about opportunity selection, investor conversations, and fundraising readiness

  • What Elena is seeing in the current market around platforms, AI-bio, grants, and JPM

  • Why community matters so much in the early scientist-to-founder transition

  • And much more!

You can watch the full interview, or listen via your podcast platform of choice below.

Listen + subscribe: Spotify / Apple Podcasts / YouTube

And while you cue those up, here are a few ideas from the conversation that stuck with me 👇

BROUGHT TO YOU BY ADP

ADP - payroll, benefits, HR, and R&D tax credit support for early-stage biotechs.

Bio Founder GPS readers get founder-friendly pricing:

  • 20–30% lifetime discount on eligible services

  • Waived sign-on fees

  • Up to 6 months of free payroll (eligibility-based)

  • Preferred pricing on HR, compliance, and benefits tools

  • R&D tax credit setup and support (up to $500K offset against payroll taxes)

MAIN TAKEAWAYS

1. Scientists may be more founder-ready than they think

One of Elena’s core beliefs is that scientist-founders are often underestimated.

And even more importantly, that they often underestimate themselves.

From the outside, people may imagine scientists as purely technical specialists: brilliant at the bench, but unprepared to lead companies.

But if you look closely at what successful scientists already do, many of the founder muscles are already there.

A scientist has to identify a meaningful problem, develop a thesis, convince others the work matters, recruit people into the lab, raise grant funding, manage limited resources, publish results, respond to criticism, and keep going through uncertainty.

Now, I don’t know about you, but that sounds pretty relevant to company-building to me.

Of course, running a company requires different instincts than running a lab. The incentives are different. The timelines are different. The stakeholders are different. The bar for translation is different.

But the raw material is there.

The job is to translate those skills into a new context.

I think that’s an important reframe for scientist-founders: you may have more founder-relevant experience than you think.

The question is how quickly you can adapt those skills to a world where the goal is no longer only to understand the biology, but to build something that can survive outside the academic system that produced it.

2. You don’t need permission to build

The part of the conversation that stuck with me most was Elena’s point about permission.

Academia trains people to seek external validation.

You need approval to run certain experiments. You need permission to publish. You need grant reviewers, peer reviewers, committees, advisors, and institutions to validate that the work matters.

That system creates rigor, but it can also create a reflex: you wait to be chosen, you wait to be told that the idea is ready.

In other words, you wait for someone else to confirm that you’re allowed to step into the next role.

Company-building requires a different posture.

At some point, the founder has to decide that the problem matters, that the company deserves to exist, and that they are willing to take responsibility for moving it forward.

Elena described seeing this shift happen over time with founders in Nest Catalyst. At the beginning, many are still looking for external confirmation that they are allowed to build. Over time, they start taking ownership of the founder role itself.

I liked that framing because it gets at something many scientist-founders feel, but may not always name.

The scientist-to-founder transition is not only about learning fundraising, hiring, BD, or regulatory strategy.

It’s also about identity.

You can know all the tactics and still struggle if some part of you is waiting for permission to lead.

3. Your beachhead deserves more scrutiny than most founders recognize

Another useful point Elena made was around opportunity selection.

In academia, you often follow the biology where it leads. That’s part of what makes science work.

But when you start a company, the question changes: you have to ask where this science should enter the world first.

That may be the same problem you were studying in the lab. Sometimes it is. But sometimes the academic starting point is simply the place where the discovery happened, not necessarily the best first market, indication, product, or beachhead for the company.

This came up several times in the conversation.

A technology may have multiple possible applications. A biological insight may point toward several disease areas. A platform may be able to generate different kinds of assets.

The hard part is choosing where to start.

And that choice affects almost everything that follows: the first experiments, the investor universe, the team you need, the regulatory path, the partnerships that matter, and the story you tell.

I think this is especially relevant for founders who feel pulled between a broad platform vision and a more focused first asset or beachhead.

You may believe the platform can do many things, and that may certainly be the case.

But the first application has to make the rest of the story easier to believe.

That means asking some uncomfortable questions early:

  • Where does this science create the clearest advantage?

  • Which problem has the strongest unmet need?

  • Where can you generate credible proof in the quickest and cheapest way?

  • Which first application creates the best next financing milestone?

  • Which investors or partners actually fund this kind of opportunity?

Those questions aren’t always easy to answer, but if you don’t make that choice deliberately, it still gets made - just later, under more pressure, and often by people with less context than you.

4. Investor conversations can start early, but the framing matters

As you probably expected, we also spent a lot of time talking about fundraising.

One useful distinction Elena made was between talking to investors and running a fundraise.

You can start investor conversations early if you are honest about where you are.

If you are still mapping the opportunity, say that. If you are still deciding which first indication or market makes sense, be clear about it.

If you are trying to understand how investors think about the space, these can be very productive conversations.

The problem comes when an early, incomplete story gets presented as though every major question has already been answered - that creates a very different signal.

If an investor sees obvious gaps and the founder cannot acknowledge them, the conversation can work against the company.

So, the framing matters.

Early conversations can definitely be useful, and can be a great way to get a market pulse and build relationships with investors.

However, a formal fundraise is a different game, and requires a different preparation.

Before launching a real raise, you should be able to tell the story from multiple angles:

  • What are you building?

  • Who is it for?

  • Why does this first market or indication make sense?

  • What evidence already exists?

  • What remains to be proven?

  • Who’s on the team?

  • How much capital do you need?

  • What milestone does that capital unlock?

  • Why does that milestone increase company value?

That last question is especially important: a fundraise is not simply about surviving another 12 to 18 months, it’s about creating the next value inflection point.

This is where Elena’s comments connected closely with how I think about round architecture.

At the end of the day, you are raising a specific amount of money to validate a specific set of assumptions that should make the company more valuable.

When that logic holds together, the fundraising conversation gets much stronger.

5. A warm investor is not always the right investor

One of the more practical parts of the conversation was around investor targeting.

Elena made a point that many founders learn the hard way: an investor can like your science and still be structurally wrong for your company.

For example: they may be the last to come into a round, they may write checks that are too small, or they may only follow once a lead is in place.

They may care about the space, but lack the mandate to invest in your modality, geography, stage, or company type.

This is especially challenging in early-stage biotech because the investor landscape is so fragmented: you have traditional biotech VCs, micro-VCs, angel groups, family offices, accelerators, disease-focused funds, pharma-adjacent programs, and individual operators who may invest personally.

They can all be useful - but remember, the different investor types don’t all play the same role.

Some can lead. Some follow. Some can write a small early check. Some can help with introductions. Some are better thought of as future Series A relationships. Some are useful sources of market feedback, but unlikely to invest.

Treating all of those conversations the same is where a lot of time gets wasted.

The better question is: what role could this person or fund realistically play in my financing strategy?

That question sounds simple, but it changes how you approach the conversation.

A FEW MORE FROM ELENA

Platforms still need a path to proof

We also talked about platforms versus assets, which continues to be one of the biggest strategic questions for early-stage biotech companies.

Elena’s view was consistent with what I’m seeing as well: platform stories can still be compelling, but investors increasingly want to understand how that platform turns into a fundable asset.

A platform can create long-term value, but at some point, the platform has to produce proof.

For many companies, that means being very clear about the first asset, first indication, or first product path that makes the broader platform easier to believe.

AI-bio needs something that others can’t copy

On AI-bio, Elena offered a useful test: if you remove “AI” from the deck, is there still a meaningful company underneath?

I liked that question.

Because if the entire company depends on generic computational capability, it may be hard to defend as models improve and tools become more accessible.

The stronger AI-bio companies usually have something else: proprietary data, unique experiments, a feedback loop, a specialized biological insight, or an ability to generate data others cannot easily replicate.

The AI itself can certainly be powerful, but the true moat usually comes from what the AI is connected to, and the flywheel that only reinforces the competitive advantage as additional data and insights are generated.

Grants are useful, but rarely simple

We also touched on grants.

There’s a common belief that grants are the natural first step for scientist-founders - and sometimes they are. But Elena pointed out that many grants require preliminary data, infrastructure, institutional support, and long timelines.

If you are still in academia, that may be more accessible. If you have already left and are trying to build independently, it can be much harder.

That doesn’t mean you should ignore non-dilutive funding, you absolutely should explore it. But grants should be part of the financing strategy, not the entire strategy.

Elena also suggested looking closely at patient organizations, especially if you’re working in rare disease or another mission-driven area with a clearly defined patient population. These groups may offer grants, but they can also become part of the early ecosystem around the company — helping with disease-area context, patient insight, advocacy relationships, and credibility.

JPM is all about the side events

Finally, we talked about JPM. Is it overrated? Too expensive?

Elena’s take was very clear: JPM can be extremely useful, even for early-stage founders, but the value is usually not the official conference badge. The value is the side-event ecosystem.

During JPM week, founders, investors, pharma teams, service providers, community builders, and operators all converge in San Francisco. That creates a rare density of people who are otherwise scattered across Boston, New York, San Diego, Europe, and beyond.

But JPM only works if you’re intentional. Showing up without a plan is expensive networking theater.

Instead, use the planning apps and other resources to schedule targeted meetings, relevant side events, thoughtful follow-ups, and a clear reason for each conversation - while still leaving just enough room for serendipity and spontaneous connections.

This one may certainly be more of an art than a science 🙂

THAT’S A WRAP!

A huge thank you to Elena for joining me and sharing such a thoughtful perspective on the scientist-founder journey.

One theme I kept coming back to is that the transition from scientist to founder is much harder to make in isolation.

You may be figuring out the first market, testing the story, deciding what proof matters, building an investor strategy, and getting comfortable leading the company — all at the same time. That’s legitimately a lot to carry alone.

This is where community matters.

Advisors, mentors, other founders, operators, investors, patient groups, and ecosystem builders can help you see the company from different angles. They can pressure-test your assumptions, point out blind spots, make useful introductions, and help you get more comfortable operating outside the academic system that trained you.

In many ways, community becomes the catalyst for the identity shift itself — helping you move from thinking like the scientist behind the idea to acting like the founder responsible for building the company.

You still have to make the decisions.

But those decisions get better when you’re surrounded by people who help you see what the company can become.

If you are a scientist-founder still in the early stages, I hope that perspective is helpful.

Resources from the conversation:

A couple of small asks before you go:

If you haven't already, hit follow on Spotify or Apple Podcasts - it genuinely helps us build momentum. And if you watch on YouTube, don't forget to subscribe.

I'd love to hear from you: Where in the scientist-founder transition are you right now? What’s your current biggest challenge? Reply to this email and let me know!

See you next week!

- Vadim

PS: Do you know a founder, an investor, or a subject matter expert that I should interview? If so, you know what to do 🙂

PPS: If you found this issue useful, the easiest way to support is to forward it to one founder who'd benefit. They can subscribe at biofounder.io